MRD testing

SEATTLE — September 25, 2026 Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma presented at...

AUSTIN, Texas — May 27, 2026 Natera, Inc. announced the enrollment of the first patients in the SIGNAL-ER 101...

FREMONT, California, May 20, 2026 Personalis announced that the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program...

Fremont, California | April 13, 2026 Personalis, Inc. has unveiled new data showcasing its ultrasensitive ctDNA-based cancer monitoring platform,...

Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...

TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at...